<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s disease.Read more... [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Peter Thiel is utterly wrong about Alzheimer's

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal founder Peter Thiel. There's a reason it was published in the opinion sect [...]

Match Score: 124.28

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 111.18

Destination
The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 98.97

Destination
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 89.31

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 86.46

Destination
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]

Match Score: 85.49

Destination
Eli Lilly's first weight-loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.Read more... [...]

Match Score: 82.81

Destination
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]

Match Score: 78.26

Destination
Eli Lilly promises to make new weight-loss pill in the U.S.

Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to [...]

Match Score: 75.78